European Primary Care Cardiovascular Society

CODE-EHR, a framework for the use of electronic health record data in clinical research

5' education - Oct. 13, 2022 - Prof. Folkert Asselbergs, MD, PhD

Risk of CVD in patients with autoimmune diseases

5' education - Oct. 12, 2022 - Prof. Naveed Sattar, MD, PhD

DOAC versus VKA in rheumatic atrial fibrillation

3' education - Sep. 15, 2022 - Prof. Ganesan Karthikeyan, MD

What are the real effects of statins on muscle symptoms?

3' education - Sep. 12, 2022 - Prof. Colin Baigent, MD

Aspirin or P2Y12i monotherapy for secondary prevention in patients with CAD?

3' education - Sep. 5, 2022 - Prof. Marco Valgimigli, MD, PhD

Long-term use of PCSK9i reduces CV events in ASCVD

3' education - Aug. 29, 2022 - Michelle O'Donoghue, MD

Smartphone-based screening more than doubles detection rate of atrial fibrillation

3' education - Aug. 28, 2022 - Prof. Axel Bauer, MD

A community-based screening trial for CVD

3' education - Aug. 28, 2022 - Prof. Axel Diederichsen, MD

Improved outcomes with SGLT2i in HFpEF and HFmrEF

3' education - Aug. 27, 2022 - Prof. Scott Solomon, MD

Patients with heart failure benefit from SGLT2i regardless of ejection fraction

3' education - Aug. 27, 2022 - Prof. Pardeep Jhund, MD, PhD

ARNI has no negative effect on cognitive function

3' education - Aug. 26, 2022 - Prof. John McMurray, MD

A discussion on CV risk reduction beyond statin therapy: Exploring the role of Icosapent ethyl

10' education - June 20, 2022 - Prof. Ulrich Laufs, MD, PhD, prof. Chris Packard, PhD and prof. Wouter Jukema, MD, PhD

What are potential mechanisms of benefit of icosapent ethyl?

10' education - June 20, 2022 - Prof. Chris Packard, PhD

Need to restart and catch up in CVD prevention in time of COVID-19

10' education - June 2, 2022 - Prof. Richard Hobbs, MD

Key findings of CV outcomes trials with icosapent ethyl

10' education - May 18, 2022 - Prof. Wouter Jukema, MD, PhD

Triglyceride-rich lipoproteins as residual CV risk in patients on statins

10' education - May 8, 2022 - Prof. Alberto Zambon, MD, PhD

Dietary education in the grocery store: a novel form of CV research

3' education - Apr. 19, 2022 - Prof. Eileen Handberg, PhD

Treating elevated Lp(a): beginning of an era

3' education - Apr. 16, 2022 - Steven Nissen, MD

Potassium binder results in optimization of RAASi and low risk of hyperkalemia in HFrEF

3' education - Apr. 14, 2022 - Prof. Javed Butler, MD

Quality of care improved with EHR-based intervention for patients with HF

3' education - Apr. 13, 2022 - Tariq Ahmad, MD

Improved use of high-intensity statin with centrally controlled individualized reminders

News - Mar. 14, 2023

ACC.23 In a multisite-RCT study was examined whether an intervention including individualized reminders sent to primary care clinicians improved use of high-intensity statin in patients with ASCVD.

Improved prescription of therapies with multifaceted intervention in T2DM and ASCVD

News - Mar. 14, 2023

ACC.23 In the COORDINATE-Diabetes trial was investigated whether a multifaceted intervention can improve prescription of 3 groups of evidence-based therapies in patients with T2DM and ASCVD.

Association between lifelong endurance exercise and higher coronary plaque burden

News - Mar. 14, 2023
Among men aged 45 to 70 years without CV risk factors, lifelong endurance athletes have a higher coronary plaque burden compared to participants who exercise up to 3 hours per week.

ACC.23 Among men aged 45 to 70 years without CV risk factors, lifelong endurance athletes have a higher coronary plaque burden compared to participants who exercise up to 3 hours per week.

LDL-c lowering with new oral PCSK9 inhibitor in hypercholesterolemia

News - Mar. 14, 2023

ACC.23 Injectable treatments may have poor adoption due to access barriers and the need for repeat injections. An oral PCSK9 inhibitor, MK-0616, was developed and tested in a phase 2b trial.

Association of self-reported keto diet with LDL-c and apoB levels and MACE

News - Mar. 14, 2023

ACC.23 UK Biobank participants who followed a low-carbohydrate high-fat diet had higher LDL-c and apoB levels and an increased risk of incident MACE compared with those on a standard diet.

Likelihood of prescribing MRA increased with EHR alert in HFrEF

News - Mar. 14, 2023

ACC.23 An EHR-embedded and selective alert delivered during the clinical encounter increased the likelihood of prescribing MRA by 2.5x in MRA-eligible HFrEF patients in an outpatient cardiology setting.

Reduction of CV events with bempedoic acid in statin-intolerant patients

News - Mar. 14, 2023

ACC.23 The CLEAR Outcomes study showed that among statin-intolerant primary and secondary prevention patients, bempedoic acid reduced the risk of the primary composite endpoint of nonfatal MI, nonfatal stroke, coronary revascularization or CV death.

Approval of SGLT2i in the EU for treatment of HF patients across full spectrum of LVEF

News - Feb. 8, 2023

The European Commission has approved dapagliflozin to extend the indication to cover HF patients across the full range of LVEF (now including HFmrEF and HFpEF).

Association between cumulative systolic blood pressure load and cardiovascular events in diabetes

Literature - Jan. 5, 2023 - Wang N et al. - J Am Coll Cardiol. 2022

In a post-hoc analysis of the ADVANCE trial, cumulative SBP load was a better predictor of the occurrence of MACE in patients with T2DM compared with other BP measures.

Lp(a) levels in children with popable FH and definite FH

Literature - Dec. 6, 2022 - De Boer LM, et al. - Eur Heart J. 2022

A Dutch cross-sectional study showed that Lp(a) levels were higher and more often elevated in children with a clinical presentation of FH in whom no FH-causing mutation was detected compared with children with a mutation and their unaffected siblings.

Low adherence and persistence with HF therapies in newly diagnosed HF patients

Literature - Nov. 29, 2022 - Ødegaard KM, et al. - ESC Heart Fail. 2022

A Norwegian nationwide cohort study showed that in newly diagnosed HF patients, 1-year adherence to dual or triple HF therapies was low and 2- to 5-year persistence was inadequate.

Physical activity in the morning associated with reduced CVD risk

Literature - Nov. 28, 2022 - Albalak G, et al. - Eur J Prev Cardiol. 2022

Sufficient physical activity lowers the risk of CV mortality and improves quality of life. However, little is known about the association between timing of physical activity and CVD risk in the general population.